Articles · Nutrition & Lifestyle
Omega-3 for Menopause: What It Helps and What It Does Not
What fish oil evidence supports during the transition, and which common claims do not hold up.
Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.
Omega-3 fatty acids are among the most widely taken supplements by women in midlife. The marketing is broad: joint health, heart health, mood, memory, hot flash relief. Some of these claims have solid evidence. Others do not. Knowing the difference matters when you are deciding whether a supplement is earning its place.
What Omega-3 Fatty Acids Are
“Omega-3” covers a family of polyunsaturated fatty acids. The two most relevant for health are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), found mainly in oily fish. A third, ALA (alpha-linolenic acid), comes from plant sources like flaxseed and walnuts, but the body converts only a small fraction of ALA into the more active EPA and DHA.
When research talks about omega-3 benefits, it almost always means EPA and DHA, from food or concentrated fish oil supplements.
What the Research Does Not Support: Hot Flashes
A 2023 systematic review of randomized controlled trials of omega-3 supplementation in postmenopausal women assessed effects on hot flashes, sleep quality, and depression.[1] The conclusion on hot flashes was clear: the combined analysis did not provide substantial evidence for improving vasomotor symptoms.
This matches the MsFLASH trial, one of the larger rigorous trials in this area. It tested omega-3 in healthy perimenopausal and postmenopausal women and found no improvement in hot flash frequency, bother, sleep, or mood compared with placebo.[2]
If you are taking omega-3 for hot flashes, the evidence does not support that use.
What the Research Does Support: Mood and Depression
The evidence for omega-3 and mood is stronger, and in the context of menopause that is clinically useful.
EPA and DHA are structural parts of brain cell membranes, including in regions involved in mood. They support mood through several mechanisms: reducing neuroinflammation, supporting neurotransmitter function (particularly serotonin and dopamine), and promoting neuroplasticity.[3]
Meta-analyses of omega-3 for depression in general adult populations show clinically meaningful effects, particularly at higher EPA doses. The evidence is strongest when EPA predominates over DHA, usually at an EPA to DHA ratio of at least 2 to 1.[3]
In menopause specifically, one cross-sectional study of postmenopausal women found an inverse link between dietary omega-3 intake and depression scores, independent of other dietary factors.[4] An earlier open trial in perimenopausal and postmenopausal women with depression found omega-3 produced clinically significant reductions in depressive symptoms over eight weeks.[5]
The picture: omega-3 has credible biological mechanisms and some trial data supporting mood benefits in menopausal women, particularly when depression or mood instability is the target, not hot flashes.
Inflammation: The Broader Relevance
Menopause is linked to more low-grade systemic inflammation. Estrogen is anti-inflammatory, and its decline raises markers such as IL-6, TNF-alpha, and CRP. This inflammatory shift contributes to joint pain, muscle loss, cognitive changes, and heart risk.
EPA is a building block for anti-inflammatory signaling and reduces production of pro-inflammatory signals including IL-6 and TNF-alpha.[6] This matters across several symptom areas, not just mood. The research on omega-3 for joint pain has enough support in osteoarthritis and rheumatoid arthritis to appear in some clinical guidelines.[6]
This anti-inflammatory effect also underlies the link between omega-3 intake and lower heart risk. During the transition, when heart risk starts to rise, maintaining adequate omega-3 intake is supported by the broader cardiovascular literature independent of menopause-specific studies.
Dietary Sources Versus Supplements
Food sources of EPA and DHA are preferable to supplements where achievable. Oily fish (salmon, mackerel, sardines, anchovies, herring) provide EPA and DHA in a food matrix with other nutrients, and food-based omega-3 intake has a stronger evidence base than supplementation across most outcomes.
A practical target from most dietary guidelines: two portions of oily fish a week, providing about 500 to 700 mg of EPA plus DHA per day.
For women who do not eat fish, algae-based omega-3 supplements provide EPA and DHA directly. Algae are the original source; fish accumulate omega-3 through the food chain. These are an evidence-based alternative with a nutrient profile similar to fish oil.
When supplementing, the evidence favors higher EPA relative to DHA for mood-related benefits. Look for combined EPA plus DHA of at least 1 gram a day with EPA predominating. The supplement market is poorly regulated and purity varies; third-party tested products (IFOS or USP certification) are a reasonable quality filter.
Evidence Summary
| Claim | Evidence status |
|---|---|
| Reduces hot flash frequency | Not supported by RCT evidence |
| Reduces depressive symptoms | Moderate support, particularly at higher EPA doses |
| Reduces systemic inflammation | Well-supported mechanistically and in RCTs |
| Supports cardiovascular health | Well-supported in broader population literature |
| Reduces joint pain | Some support in arthritis literature |
Omega-3 supplementation or consistent dietary intake is worth considering during the transition, mainly for its anti-inflammatory, cardiovascular, and mood-related effects. It is not a treatment for hot flashes. Much of the supplement marketing presents it as one, which overstates the evidence and may lead women to prioritize it over more effective options for their main symptom.
References
[1] Mehdizadeh, A., Ghazanfarpour, M., Heshmat-Ghahdarijani, K., et al. (2023). Effects of omega-3 polyunsaturated fatty acids intake on vasomotor symptoms, sleep quality and depression in postmenopausal women: A systematic review. Post Reproductive Health, 29(4). https://pmc.ncbi.nlm.nih.gov/articles/PMC10574492/
[2] Cohen, L. S., Joffe, H., Guthrie, K. A., et al. (2014). Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial. Menopause, 21(4), 347-354. https://pmc.ncbi.nlm.nih.gov/articles/PMC4072122/
[3] Liao, Y., Xie, B., Zhang, H., et al. (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry, 9, 190. See also: Omega-3 polyunsaturated fatty acids in depression. https://pmc.ncbi.nlm.nih.gov/articles/PMC11354246/
[4] Chiu, C. C., Su, K. P., Cheng, T. C., et al. (2021). Association between dietary omega-3 fatty acid intake and depression in postmenopausal women. Nutrients, 13(7). https://pmc.ncbi.nlm.nih.gov/articles/PMC8313386/
[5] Lucas, M., Asselin, G., Merette, C., Poulin, M. J., Dodin, S. (2009). Omega-3 fatty acids for major depressive disorder associated with the menopausal transition: a preliminary open trial. European Neuropsychopharmacology, 19(12), 897-904. https://pubmed.ncbi.nlm.nih.gov/21037490/
[6] Calder, P. C. (2015). Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochimica et Biophysica Acta, 1851(4), 469-484. https://doi.org/10.1016/j.bbalip.2014.08.010
Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.